Intravenous alprostadil requires respiratory monitoring during administration because apnea develops in 10—12% of neonates.
Intravenous Alprostadil erfuerdert respiratoresch Iwwerwachung bei der Verwaltung, well d'Apnoe am 10-12% vun Neonatum entwéckelt.